Avience Biomedicals IPO- Company Analysis
Avience Biomedicals IPO under the SME IPO category is a bookbuild issue of Rs. 30.24 Cr by Avience Biomedicals Limited and an ISO-certified business that focuses on biotechnology, genomics, and the IVD sector while producing, delivering, and exporting molecular diagnostic products.
Avience Biomedicals Limited now offers a wide range of medical devices, including biochemistry analyzers and serology products, in addition to IVD fast test kits. This shows a dedication to meeting a variety of healthcare demands while concentrating on the B2B and B2G industries.
The company's products are used by hospitals, research centers, pathology labs, and microbiology labs both domestically and abroad. The company distributes and trades medical equipment in addition to making it.
The business provides a wide range of diagnostic services, such as:
-
Quick Test Kits
-
Reagents and Analyzers for Biochemistry
-
Molecular Diagnostics
-
Analyzers for hematology
-
Hematology Analyzer.
-
Medical Equipment
Avience Biomedicals IPO Details
The Avience Biomedicals IPO date of opening is 18 Jun 2026, its initial public offering will end on 22 Jun, IPO allotment on Jun 23 and refund initiation on Jun 24, 2026.
The Rs. 30.24 crore new SME IPO comprises a wholly fresh issue of 0.15 crore Shares.
The Avience Biomedicals IPO listing date (expected) might be Thursday, Jun 25, 2026, and listing at the NSE and SME.
The Avience Biomedicals IPO price band is Rs. 196 to Rs. 208.
IPO Timetable (Tentative)
|
Events |
Date |
|
IPO Opening Date |
Jun 18, 2026 |
|
IPO Closing Date |
Jun 22, 2026 |
|
IPO Allotment Date |
Jun 23, 2026 |
|
Refund Initiation |
Jun 24, 2026 |
|
IPO Listing Date |
Jun 25, 2026 |
Click to open demat account and apply for the IPO.
Company Financials
(Amount in Cr)
|
Particulars |
31 Jan 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Assets |
66.07 |
56.52 |
34.65 |
|
Total Income |
41.94 |
45.97 |
24.37 |
|
Profit After Tax |
5.74 |
7.23 |
2.14 |
|
EBITDA |
10.34 |
11.41 |
4.08 |
|
Net Worth |
28.52 |
22.78 |
6.21 |
|
Reserves and Surplus |
24.49 |
18.75 |
2.93 |
|
Total Borrowing |
26.73 |
22.16 |
15.13 |
Cash Flows
(Amount in lac)
|
Net Cash Flow |
31 Jan 2026 |
31 Mar 2025 |
31 Mar 2024 |
|
Net Cash Flow Operating Activities |
277.79 |
360.63 |
98.50 |
|
Net Cash Flow Investing Activities |
(903.53) |
(880.59) |
(402.77) |
|
Net Cash Flow Financing Activities |
306.74 |
925.37 |
296.72 |
Revenue Bifurcation
(Rs. in Lac)
(Source: RHP)
The Objective of the Issue
The company desires to use the Net Proceeds from the Issue to fulfill its following goals:
-
Part finances the capital expenditure towards setting up a new manufacturing unit at industrial plot no. 70, Sector 28 in the Medical Device Park under the Yamuna Expressway Industrial Development Authority (YEIDA), Gautam Buddha Nagar, Uttar Pradesh. ~Rs. 15.96 Cr.
-
Funding the working capital requirements of the Company. ~ Rs. 8.25 Cr.
-
General Corporate Purposes.
Listed Peers of Avience Biomedicals Ltd.
No listed peer of a similar size is engaged in the same lines of business as mentioned in the RHP.
Valuation
|
KPI |
Value (Mar 31, 2025) |
|
RoE |
38.64% |
|
ROCE |
21.68% |
|
Debt/Equity |
0.67 |
|
RoNW |
38.64% |
|
PAT Margin |
15.86% |
|
EBITDA Margin |
26.49% |
|
Price to Book Value |
4.09 |
Evaluation of P/E Ratio
Considering the period ended on FY 2025 with an EPS of Rs. 19.06 from the last year, the resulting P/E ratio is 10.91x.
Explore the Hexagon Nutrition IPO.
IPO's Strengths
-
Strong Industry Experience and Expertise.
-
Avience provides various diagnostic products, including rapid test kits, analyzers, hematology devices, and molecular kits.
-
Strong distribution network across India and is growing its international footprint.
-
Cost-Effective and Affordable Solutions.
IPO's Weaknesses
-
Dependence on Key Suppliers.
-
High Research and Development Costs.
-
Intense Competition.
-
Regulatory Challenges.
Avience Biomedicals IPO GMP (Grey Market Premium)
Avience Biomedicals IPO GMP today is Rs. 40, as of 15 June 2026, while writing this information.
Avience Biomedicals IPO Summary
|
IPO Opening & Closing Date |
18 Jun, 2026 to 22 Jun, 2026 |
|
Face Value |
Rs. 10 per Share |
|
Issue Price |
Rs. 196 to Rs. 208 per Share. |
|
Lot Size |
600 Shares |
|
Issue Size |
14,53,800 Shares (Rs. 30 Cr) |
|
Offer for Sale |
- |
|
Fresh Issue |
13,71,600 Shares (Rs. 29 Cr) |
|
Listing at |
NSE, SME |
|
Issue Type |
Book build Issue |
|
Registrar |
Skyline Financial Services Pvt. Ltd. |
IPO Lot Details
Retail investors can invest in a minimum and maximum of 2 Lots (1200 Shares) for Rs. 2,49,600, and in multiples thereof, while HNI investors can invest in a minimum of 3 Lots (1800 Shares) for Rs. 3,74,400.
|
Minimum Lot Investment (Retail) |
2 Lots |
|
Maximum Lot Investment (Retail) |
2 Lots |
|
HNI (Min) |
3 Lots |
Avience Biomedicals IPO Allotment Status
To check the Avience Biomedicals IPO Allotment Status, visit the official Registrar’s website or BSE website. Below are the website links for you.
Using BSE Website - BSE IPO allotment status
Promoters And Management of Avience Biomedicals Ltd.
-
Mr. Dharam Deo Choudhary
-
Mr. Ram Nagina Choudhary
-
Mr. Janardan Pal
-
Ms. Deepa Choudhary.
|
Pre-Issue Promoter Shareholding |
87.89% |
|
Post-Issue Promoter Shareholding |
64.59% |
IPO Lead Managers
Fintellectual Corporate Advisors Pvt. Ltd.
Dividend Policy
The company has not paid a dividend during the last three financial years.
Conclusion
Avience Biomedicals IPO presents a strong growth opportunity in the biotechnology and IVD diagnostics sector with diversified product offerings and expanding domestic and international presence.
The company shows healthy financial performance with strong margins, improving returns, and controlled leverage. However, investors should note risks related to competition, regulatory dependency, and high R&D costs before investing.
Other Related Blogs:-
Aureate Tradde IPO
